Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avapritinib for advanced systemic mastocytosis.

Blood - 13 Oct 2022

Gotlib Jason, Reiter Andreas, DeAngelo Daniel J

Abstract excerpt

Avapritinib, a highly selective inhibitor of KIT D816V, was approved by the Food and Drug Administration in 2021 for treatment of advanced systemic mastocytosis (AdvSM) and by the European Medicines Agency in 2022 for AdvSM after prior systemic therapy. The phase 1 EXPLORER and phase 2 PATHFINDER trials demonstrated that avapritinib can elicit complete and durable clinical responses and molecular remission of KIT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrazoles
Share to Pyrroles
Share to Triazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mastocytosis

Share to Mastocytosis, Systemic

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 35877999
DOI: 10.1182/blood.2021014612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avapritinib for advanced systemic mastocytosis.PMID 35877999Read ↗

Avapritinib for Systemic Mastocytosis.Semantic proximity Read ↗

Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms.Semantic proximity Read ↗

Systemic Mastocytosis: State of the Art.Semantic proximity Read ↗

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.Semantic proximity Read ↗

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.Semantic proximity Read ↗

Avapritinib: First Approval.Semantic proximity Read ↗

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.Semantic proximity Read ↗

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors in Non-advanced Systemic Mastocytosis.Semantic proximity Read ↗

Systemic mastocytosis for the practicing clinician: overview, diagnostic features, prognostication and antiproliferative treatment in the era of targeted therapy.Semantic proximity Read ↗

Systemic Mastocytosis in Adults: 2026 Update on Diagnosis, Risk Stratification and Management.Semantic proximity Read ↗

Targeted therapy in KITD816V-positive mastocytosis: waiting for proof-of-principle.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.